SALT LAKE CITY, Sept. 16, 2019 /PRNewswire/ —DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that the first 30 subjects have been safely treated its first-in-human U.S. clinical study of IDCT, an allogeneic, injectable disc cell therapy …